Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 103

1.

Differential characteristics of Waldenström macroglobulinemia according to patterns of familial aggregation.

Royer RH, Koshiol J, Giambarresi TR, Vasquez LG, Pfeiffer RM, McMaster ML.

Blood. 2010 Jun 3;115(22):4464-71. doi: 10.1182/blood-2009-10-247973. Epub 2010 Mar 22.

2.

Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia.

Kristinsson SY, Koshiol J, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O.

J Natl Cancer Inst. 2010 Apr 21;102(8):557-67. doi: 10.1093/jnci/djq043. Epub 2010 Feb 24.

3.

Medical history, lifestyle, family history, and occupational risk factors for lymphoplasmacytic lymphoma/Waldenström's macroglobulinemia: the InterLymph Non-Hodgkin Lymphoma Subtypes Project.

Vajdic CM, Landgren O, McMaster ML, Slager SL, Brooks-Wilson A, Smith A, Staines A, Dogan A, Ansell SM, Sampson JN, Morton LM, Linet MS.

J Natl Cancer Inst Monogr. 2014 Aug;2014(48):87-97. doi: 10.1093/jncimonographs/lgu002.

4.

Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden.

Kristinsson SY, Björkholm M, Goldin LR, McMaster ML, Turesson I, Landgren O.

Blood. 2008 Oct 15;112(8):3052-6. doi: 10.1182/blood-2008-06-162768. Epub 2008 Aug 13.

5.

Elevated risk of venous but not arterial thrombosis in Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.

Hultcrantz M, Pfeiffer RM, Björkholm M, Goldin LR, Turesson I, Schulman S, Landgren O, Kristinsson SY.

J Thromb Haemost. 2014 Nov;12(11):1816-21. doi: 10.1111/jth.12724. Epub 2014 Oct 6.

6.

Familial Waldenstrom's macroglobulinemia and relation to immune defects, autoimmune diseases, and haematological malignancies--A population-based study from northern Sweden.

Brandefors L, Kimby E, Lundqvist K, Melin B, Lindh J.

Acta Oncol. 2016;55(1):91-8. doi: 10.3109/0284186X.2015.1096019. Epub 2015 Nov 11.

PMID:
26559865
7.

Familial Waldenstrom's macroglobulinemia.

McMaster ML.

Semin Oncol. 2003 Apr;30(2):146-52.

PMID:
12720125
8.

Familial disease predisposition impacts treatment outcome in patients with Waldenström macroglobulinemia.

Treon SP, Tripsas C, Hanzis C, Ioakimidis L, Patterson CJ, Manning RJ, Sheehy P, Turnbull B, Hunter ZR.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):433-7. doi: 10.1016/j.clml.2012.08.006. Epub 2012 Oct 17.

PMID:
23084402
9.

Chronic immune stimulation and subsequent Waldenström macroglobulinemia.

Koshiol J, Gridley G, Engels EA, McMaster ML, Landgren O.

Arch Intern Med. 2008 Sep 22;168(17):1903-9. doi: 10.1001/archinternmed.2008.4.

10.

Familial aggregation of lymphoplasmacytic lymphoma/Waldenström macroglobulinemia with solid tumors and myeloid malignancies.

Kristinsson SY, Goldin LR, Turesson I, Björkholm M, Landgren O.

Acta Haematol. 2012;127(3):173-7. doi: 10.1159/000335618. Epub 2012 Feb 3. Review.

11.

Long-term evaluation of three multiple-case Waldenstrom macroglobulinemia families.

McMaster ML, Csako G, Giambarresi TR, Vasquez L, Berg M, Saddlemire S, Hulley B, Tucker MA.

Clin Cancer Res. 2007 Sep 1;13(17):5063-9.

12.

Associated malignancies in patients with Waldenström's macroglobulinemia and their kin.

Hanzis C, Ojha RP, Hunter Z, Manning R, Lewicki M, Brodsky P, Ioakimidis L, Tripsas C, Patterson CJ, Sheehy P, Treon SP.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):88-92. doi: 10.3816/CLML.2011.n.016.

PMID:
21454200
13.

Family history of non-hematologic cancers among Waldenstrom macroglobulinemia patients: a preliminary study.

Ojha RP, Hanzis CA, Hunter ZR, Greenland S, Offutt-Powell TN, Manning RJ, Lewicki M, Brodsky PS, Ioakimidis L, Tripsas CK, Patterson CJ, Sheehy P, Singh KP, Treon SP.

Cancer Epidemiol. 2012 Jun;36(3):294-7. doi: 10.1016/j.canep.2011.10.010. Epub 2011 Nov 17.

PMID:
22099500
14.

Associated cancers in Waldenström macroglobulinemia: clues for common genetic predisposition.

Morra E, Varettoni M, Tedeschi A, Arcaini L, Ricci F, Pascutto C, Rattotti S, Vismara E, Paris L, Cazzola M.

Clin Lymphoma Myeloma Leuk. 2013 Dec;13(6):700-3. doi: 10.1016/j.clml.2013.05.008. Epub 2013 Sep 24.

PMID:
24070824
15.

Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.

Castillo JJ, Olszewski AJ, Hunter ZR, Kanan S, Meid K, Treon SP.

Cancer. 2015 Jul 1;121(13):2230-6. doi: 10.1002/cncr.29334. Epub 2015 Mar 10.

16.

Waldenström's macroglobulinemia: incidence patterns in the United States, 1988-1994.

Groves FD, Travis LB, Devesa SS, Ries LA, Fraumeni JF Jr.

Cancer. 1998 Mar 15;82(6):1078-81.

PMID:
9506352
17.

Inherited polymorphisms in hyaluronan synthase 1 predict risk of systemic B-cell malignancies but not of breast cancer.

Kuppusamy H, Ogmundsdottir HM, Baigorri E, Warkentin A, Steingrimsdottir H, Haraldsdottir V, Mant MJ, Mackey J, Johnston JB, Adamia S, Belch AR, Pilarski LM.

PLoS One. 2014 Jun 20;9(6):e100691. doi: 10.1371/journal.pone.0100691. eCollection 2014.

18.

Community-acquired infections associated with increased risk of lymphoplasmacytic lymphoma/Waldenström macroglobulinaemia.

McShane CM, Murray LJ, Engels EA, Anderson LA.

Br J Haematol. 2014 Mar;164(5):653-8. doi: 10.1111/bjh.12671. Epub 2013 Nov 26.

19.

Cytogenetics of familial Waldenstrom's macroglobulinemia: in pursuit of an understanding of genetic predisposition.

McMaster ML, Giambarresi T, Vasquez L, Goldstein AM, Tucker MA.

Clin Lymphoma. 2005 Mar;5(4):230-4.

PMID:
15794854
20.

Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.

Castillo JJ, Olszewski AJ, Kanan S, Meid K, Hunter ZR, Treon SP.

Br J Haematol. 2015 Apr;169(1):81-9. doi: 10.1111/bjh.13264. Epub 2014 Dec 18.

PMID:
25521528

Supplemental Content

Support Center